Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.
Specifications
Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894735
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.
Specifications
Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894735
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.
Specifications
Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: IgG1
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
RRID: AB_2894735
Molecular Weight: 150 kDa